Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Daunorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.99 |
| ▸ | MEN1 | O00255 | 10/20 | 1.00 |
| ▸ | THRB | P10828 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 10/20 | 1.00 |
| ▸ | BLM | P54132 | 9/20 | 1.00 |
| ▸ | RECQL | P46063 | 8/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | USP2 | O75604 | 5/20 | 1.00 |
| ▸ | S100A4 | P26447 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Daunorubicin SCHEMBL31326687 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL142541 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL31725676 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL4445 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL4444 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL4659664 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL20185623 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL2217102 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL20204237 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL29462666 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11986489-B2 | Method of treating a disease using a glycolytic dependent compound | ETHICON, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240091196-A1 | USE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE(III)] FOR THE TREATMENT OF CANCER | BOLD THERAPEUTICS INC (CA) | 2024-03-21 | — | — | US | disclosed |
| EP-3334471-B1 | IMPROVED CANCER TREATMENT WITH DOXORUBICIN | ETHICON INC (US) | 2023-06-21 | — | — | EP | disclosed |
| US-11633380-B2 | Use of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] for the treatment of cancer | BOLD THERAPEUTICS, INC. (CA) | 2023-04-25 | — | — | US | disclosed |
| CN-114617958-A | Yeast-MUC 1 immunotherapeutic compositions and uses thereof | 全球免疫股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-20220054527-A1 | METHOD OF TREATING A DISEASE USING A GLYCOLYTIC DEPENDENT COMPOUND | OMRIX BIOPHARMACEUTICALS LTD. (IL) | 2022-02-24 | — | — | US | disclosed |
| EP-3300601-B1 | FIXED DRUG RATIOS FOR TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS | ROTALEC IP HOLDINGS LLC (US) | 2022-01-12 | — | — | EP | disclosed |
| US-11065318-B2 | Yeast-MUC1 immunotherapeutic compositions and uses thereof | GLOBEIMMUNE, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210154224-A1 | METHOD OF TREATING A DISEASE USING A GLYCOLYTIC DEPENDENT COMPOUND | ETHICON INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10960021-B2 | Method of treating a disease using a glycolytic dependent compound | OMRIX BIOPHARMACEUTICALS LTD. (IL) | 2021-03-30 | — | — | US | disclosed |
| WO-2011050068-A2 | BIVALENT DIAZO BICYCLIC SMAC MIMETICS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20100303895-A1 | FIXED DRUG RATIOS FOR TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS | CELATOR PHARMACEUTICALS, INC. | 2010-12-02 | — | — | US | disclosed |
| WO-2010133700-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MICROBUBBLES FOR TARGETED TUMOR THERAPY | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2010-11-25 | — | — | WO | disclosed |
| EP-2253308-A1 | Pharmaceutical composition comprising microbubbles for targeted tumor therapy | Ludwig-Maximilians-Universität München (DE) | 2010-11-24 | — | — | EP | disclosed |
| WO-2010127271-A1 | POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100278928-A1 | POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| EP-2120568-A2 | FIXED DRUG RATIOS FOR TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS | Celator Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080199515-A1 | FIXED DRUG RATIOS FOR TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS | Jazz Pharmaceuticals Therapeutics, Inc. | 2008-08-21 | — | — | US | disclosed |
| WO-2008101214-A2 | FIXED DRUG RATIOS FOR TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS | CELATOR PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2007137170-A2 | ANTI-GLYPICAN-3 ANTIBODY DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633380-B2 | Use of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] for the treatment of cancer | HSP90B1, HSPA5, HSPB1 | TOP2A 156/4885MEN1 4760/4885THRB 841/4885 |
| US-20240091196-A1 | USE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE(III)] FOR THE TREATMENT OF CANCER | HSPB1, TAP1, HSP90AB1 | TOP2A 101/4885MEN1 4663/4885THRB 766/4885 |
| US-20100278928-A1 | POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER | ABCB4, TOP2A, ANXA5 | TOP2A 2/4885MEN1 337/4885THRB 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.